Diabetes patients in the US will have greater flexibility in managing insulin delivery after Insulet announced its Omnipod pump is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous ...
"FreeStyle Libre technology was designed from the start to be affordable and accessible," said Jared Watkin, senior vice president for Abbott's diabetes care business. "We've been focused on ...
The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class I, the most serious designation the agency can hand out for a recall. The ...
Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...
Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...
Fresh off receiving a long-awaited FDA clearance for its FreeStyle Libre 3 system, Abbott has racked up yet another major win for the continuous glucose monitor. Clinical results presented at the ...
The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...
Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...
The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...
Abbott has recalled the FreeStyle Libre Glucose Monitors due to the risk of extreme heat and fire. The FDA has identified the recall as Class 1, the most severe type of recall. Product models consist ...
How Much Can Abbott's Price Gain If FreeStyle Libre Gets 30% of The Blood Glucose Monitoring Market?
Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results